No Data
New Capital HD ETC [Stocks with attractive features based on changes in Volume]
Stock closing prices compared to the previous day Volume <6538> Disruptors 189,397,392,400 <2776> Shinto HD 161,101,772,580 <9165> Qualtech 130,368,422,200 <2437> Shinwa 297,523,314,900 <3803> Image Information 51,233,245,500 <2983> R Planner 142,417,450,680 <1622> Automobiles 291,003,753,749 <2962> Technisco 3,021.
K Pharma: Financial results presentation materials for the 3rd quarter of the fiscal year ending 2024/12
K Pharma: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Asahi, Matsukiyo, Dentsu Group, Lancers (14th) (1379-4990)
※The above calendar is merely a schedule and may be subject to change due to the company's circumstances. --------------------------------------- November 14 (Thursday) <1379> Hokuto <1380> Akikawa Bokuen <142A> Jinjibu <1438> Gifu Landscape <1443> Giken HD <1446> Candiule <1447> SAAF HD <145A> El
Dentsu Group revised downwards to 107.1 billion yen in operating profit, from 135.4 billion yen on 24 December.
Dentsu Group (4324) announced a revision of its financial estimates for the fiscal year ending in December 2024, lowering its operating profit from 135.4 billion yen to 107.1 billion yen due to anticipated revenue deficits in Asia-Pacific regions such as China and Australia, resulting in impairment losses. Additionally, expenses related to the sale of its business in Russia, against the background of the Ukrainian invasion, have exceeded expectations. Plus evaluation: Skylark (3197), Medpeer (6095), Yonshan Holdings (3962).
K Pharma: Financial results announcement for the second quarter (interim period) of December 2024, based on Japanese accounting standards (non-consolidated).